Rigel Pharmaceuticals (NASDAQ: RIGL) kicked off on Friday, down -3.95% from the previous trading day, before settling in for the closing price of $19.73. Over the past 52 weeks, RIGL has traded in a range of $7.48-$29.82.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 30.35%. While this was happening, its average annual earnings per share was recorded 110.72%. With a float of $17.39 million, this company’s outstanding shares have now reached $17.87 million.
Considering the fact that the conglomerate employs 164 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 89.64%, operating margin of 21.63%, and the pretax margin is 18.77%.
Rigel Pharmaceuticals (RIGL) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Rigel Pharmaceuticals is 2.71%, while institutional ownership is 78.81%. The most recent insider transaction that took place on Feb 04 ’25, was worth 42,595. In this transaction EVP & Chief Financial Officer of this company sold 2,036 shares at a rate of $20.92, taking the stock ownership to the 58,969 shares. Before that another transaction happened on Feb 05 ’25, when Company’s EVP & Chief Financial Officer sold 1,734 for $21.93, making the entire transaction worth $38,020. This insider now owns 57,235 shares in total.
Rigel Pharmaceuticals (RIGL) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 110.72% per share during the next fiscal year.
Rigel Pharmaceuticals (NASDAQ: RIGL) Trading Performance Indicators
Take a look at Rigel Pharmaceuticals’s (RIGL) current performance indicators. Last quarter, stock had a quick ratio of 2.13. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.67. Likewise, its price to free cash flow for the trailing twelve months is 9.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.07, a number that is poised to hit 1.17 in the next quarter and is forecasted to reach 1.88 in one year’s time.
Technical Analysis of Rigel Pharmaceuticals (RIGL)
Compared to the last year’s volume of 0.24 million, its volume of 0.26 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 60.55%. Additionally, its Average True Range was 1.38.
During the past 100 days, Rigel Pharmaceuticals’s (RIGL) raw stochastic average was set at 34.78%, which indicates a significant increase from 24.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.22% in the past 14 days, which was lower than the 63.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.64, while its 200-day Moving Average is $18.22. Nevertheless, the first resistance level for the watch stands at $19.45 in the near term. At $19.95, the stock is likely to face the second major resistance level. The third major resistance level sits at $20.52. If the price goes on to break the first support level at $18.38, it is likely to go to the next support level at $17.81. Now, if the price goes above the second support level, the third support stands at $17.31.
Rigel Pharmaceuticals (NASDAQ: RIGL) Key Stats
The company with the Market Capitalisation of 338.68 million has total of 17,872K Shares Outstanding. Its annual sales at the moment are 179,280 K in contrast with the sum of 17,490 K annual income. Company’s last quarter sales were recorded 53,330 K and last quarter income was 11,450 K.
